SWOG
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
JAMA Oncology Study Confirms Oncotype DX Test Effectiveness Across All Racial and Ethnic Groups
• Comprehensive JAMA Oncology review validates that the Oncotype DX Breast Recurrence Score test accurately predicts chemotherapy benefit for breast cancer patients regardless of race or ethnicity.
• The largest real-world SEER registry analysis to date, involving over 171,000 breast cancer patients, provides new evidence supporting the test's consistent performance across diverse populations.
• Despite a 40% higher breast cancer mortality rate among non-Hispanic Black women compared to non-Hispanic White women, the study confirms the test's reliability in guiding precision treatment decisions for all patients.
ctDNA Status Predicts Celecoxib Benefit in Stage III Colon Cancer
• A subgroup analysis of the CALGB/SWOG 80702 trial reveals that positive circulating tumor DNA (ctDNA) status is associated with poorer disease-free survival (DFS) in stage III colon cancer.
• Celecoxib significantly improved DFS outcomes in ctDNA-positive patients compared to placebo, suggesting a potential targeted treatment approach.
• Patients with ctDNA-negative disease showed similar outcomes with celecoxib or placebo, highlighting ctDNA status as a predictive biomarker.
• The findings support using post-resection ctDNA status to guide adjuvant treatment decisions and improve survival strategies for colon cancer patients.
Celecoxib Improves Outcomes in Colon Cancer Patients with Residual ctDNA
• A new analysis shows that stage III colon cancer patients with detectable circulating tumor DNA (ctDNA) after surgery may benefit from celecoxib treatment.
• The study found that celecoxib significantly improved disease-free survival in patients with positive ctDNA tests compared to placebo.
• The findings suggest ctDNA testing could help personalize adjuvant therapy, identifying patients most likely to benefit from celecoxib.
• Researchers emphasize the need for further studies to identify additional biomarkers and optimize treatment strategies for colon cancer.
Daratumumab Plus Lenalidomide Significantly Enhances Outcomes in Newly Diagnosed Multiple Myeloma
• The AURIGA trial demonstrated a significantly higher MRD-negative conversion rate at 12 months with daratumumab plus lenalidomide compared to lenalidomide alone (50.5% vs 10.8%).
• Patients receiving daratumumab and lenalidomide achieved deeper complete responses (75.8% vs 61%) and improved progression-free survival at 30 months (83% vs 66%).
• The combination therapy showed a 47% reduction in the risk of progression or death, favoring daratumumab and lenalidomide over lenalidomide alone.
• While adverse events were slightly higher in the daratumumab/lenalidomide arm, no new safety signals were identified beyond expected cytopenia and infection.
Phase 3 Trial Shows No Overall Survival Benefit with Nab-Paclitaxel Addition in Advanced Biliary Tract Cancer
• A phase 3 trial (SWOG S1815) evaluated the addition of nab-paclitaxel to gemcitabine and cisplatin (GAP) in advanced biliary tract cancer (BTC).
• The study found no statistically significant improvement in overall survival (OS) with the GAP regimen compared to gemcitabine and cisplatin (GC) alone.
• The GAP regimen was associated with increased toxicity, including hematologic and non-hematologic adverse events, compared to the GC regimen.
• Exploratory analyses suggested potential benefits of GAP in specific subgroups, such as locally advanced disease and gallbladder carcinoma, but these were not statistically significant.
Huntsman Cancer Institute Joins myeloMATCH to Advance Precision Medicine for Blood Cancers
• Huntsman Cancer Institute joins myeloMATCH, an NCI-sponsored program, to match AML and MDS patients with tailored clinical trials based on their genetic profiles.
• The myeloMATCH program utilizes advanced technology to detect measurable residual disease (MRD), guiding treatment assignments for improved patient outcomes.
• This initiative expands treatment options, especially for older or frail patients unsuitable for aggressive chemotherapy or bone marrow transplants.
• The program integrates resources from multiple clinical trial networks, aiming to accelerate the development of personalized therapies for blood cancers.
Natera's Signatera Guides Personalized Treatment in Phase III Colon Cancer Trial
• Natera's SAGITTARIUS trial uses Signatera to personalize colon cancer treatment strategies, marking a shift from the one-size-fits-all approach.
• The trial randomizes Signatera-positive patients to genotype-guided therapy or standard chemotherapy, exploring immunotherapy and targeted agents.
• Signatera-negative patients in the study will receive physician's choice of treatment, including observation or single-agent capecitabine.
• The SAGITTARIUS project, funded by the EU, involves 9 partners across Europe and 26 clinical centers, aiming for cost-effective, tailored treatments.
PROSPECT-Lung Trial Investigates Optimal Timing of Immunotherapy in Non-Small Cell Lung Cancer
• The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer.
• This pragmatic trial aims to reflect real-world treatment decisions and provide clearer guidance on integrating immunotherapy into lung cancer treatment regimens.
• The study will enroll 1,100 patients across multiple sites in the United States and is led by the Alliance for Clinical Trials in Oncology and the SWOG Cancer Research Network.
• PROSPECT-Lung is the first trial to open through the NCI's Clinical Trials Innovation Unit, designed to accelerate cancer treatment development.
Novel Treatment Strategies Emerge for Neuroendocrine Tumors: From Surveillance to CAPTEM Therapy
• New data supports observation strategy for small pancreatic neuroendocrine tumors under 2cm, with only 1 in 500 patients showing metastatic progression during surveillance.
• CAPTEM (capecitabine and temozolomide) demonstrates improved progression-free survival in metastatic neuroendocrine tumors, emerging as a promising cytotoxic treatment option.
• The ongoing SWOG S2104 study is evaluating CAPTEM as adjuvant therapy for high-risk patients, who show up to 100% recurrence rate at 3 years post-surgery.
FDA Updates Fludarabine Phosphate Labeling for CLL Treatment
• The FDA has updated the labeling for fludarabine phosphate, expanding its approved use in treating B-cell chronic lymphocytic leukemia (CLL).
• Fludarabine phosphate is now indicated for CLL patients as part of combination regimens and for those who have progressed on alkylating agents.
• The updated label includes revised dosage recommendations when fludarabine phosphate is used with cyclophosphamide and rituximab.
• The label update also highlights potential risks, such as neurological toxicities and myelosuppression, and provides dosage guidelines for combination therapies.
VA Receives Grant to Expand Cancer Clinical Trial Access for Veterans
• The North Florida/South Georgia Veterans Health System received a SWOG/Hope Foundation grant to boost cancer research and clinical trial access for veterans.
• The grant will fund an additional research coordinator to expand clinical trial opportunities within the Veterans Health System.
• The initiative aims to broaden the SWOG clinical trial partnership, extending enrollment to other VA sites including Tampa and Miami.
• The Storefront model will coordinate multiple VA Medical Centers, enhancing data sharing and administrative efficiency across sites.
Nivolumab Plus AVD Prolongs Progression-Free Survival in Advanced Hodgkin Lymphoma
• A phase 3 trial (SWOG S1826) demonstrated that nivolumab plus AVD significantly prolonged progression-free survival (PFS) compared to brentuximab vedotin plus AVD in advanced-stage Hodgkin lymphoma.
• The 2-year PFS rate with nivolumab plus AVD was 92% compared to 83% with brentuximab vedotin plus AVD, showing a substantial improvement in disease control.
• Nivolumab plus AVD was also associated with a more tolerable safety profile, suggesting it could become a preferred first-line treatment option.
• The study's collaborative design across adult and pediatric oncology centers expedited the trial and ensured broad applicability of the findings.
Nivolumab Plus AVD Regimen Shows Superior Outcomes in Advanced Hodgkin Lymphoma
• A clinical trial demonstrated that nivolumab combined with AVD chemotherapy significantly improves progression-free survival in advanced Hodgkin lymphoma patients.
• The nivolumab-AVD regimen resulted in a 92% two-year progression-free survival rate, compared to 83% with the standard brentuximab-AVD treatment.
• Patients receiving nivolumab-AVD experienced fewer overall and serious side effects, potentially reducing the need for radiation therapy.
• Experts anticipate nivolumab-AVD will become the new standard of care, especially benefiting older patients who often face poorer outcomes.
Extended Lymph Node Removal Fails to Improve Survival in Muscle-Invasive Bladder Cancer
• A recent clinical trial found that extended lymph node removal during bladder cancer surgery does not improve overall or disease-free survival compared to standard removal.
• The study, involving 600 patients with muscle-invasive bladder cancer, showed no statistically significant survival differences after a median follow-up of 6.1 years.
• Extended lymph node removal was associated with a higher risk of serious side effects and post-operative mortality.
• Experts suggest the findings may lead to a shift towards more selective use of extended lymph node dissection, reducing unnecessary harm to patients.
Landmark Breast Cancer Trials Reshape Treatment Paradigms for HR-positive, HER2-negative Disease
• KEYNOTE-756 explores chemoimmunotherapy's role in high-risk HR-positive, HER2-negative breast cancer, showing improved pathologic complete response rates, but event-free survival data is pending.
• The FDA approved adjuvant ribociclib based on the NATALEE trial, broadening CDK4/6 inhibitor eligibility to include lower-risk patients with HR-positive, HER2-negative breast cancer.
• MonarchE trial data supports adjuvant abemaciclib for high-risk patients, demonstrating a 6% absolute difference in invasive disease-free survival, but diarrhea management is crucial.
• Treatment decisions now involve navigating side effect profiles, therapy duration, and individual risk factors when choosing between abemaciclib and ribociclib for eligible patients.
NIH Launches myeloMATCH Trial to Personalize Treatment for Myeloid Cancers
• The NIH has initiated the myeloMATCH trial, a precision medicine study for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
• The trial employs rapid genetic testing to match patients with targeted treatments based on their tumor's molecular characteristics.
• myeloMATCH aims to enroll thousands of participants, using samples to refine assays and understand treatment resistance.
• This initiative is part of the Cancer Moonshot program, aiming to improve cancer treatment and reduce mortality.
myeloMATCH Program Launches Precision Medicine Trials for AML and MDS
• The myeloMATCH program, a collaboration of leading cancer research organizations, has begun enrolling patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) for precision medicine trials.
• The program offers advanced biomarker testing to identify genomic and molecular features, matching patients with targeted treatments in a series of Phase 2 studies.
• myeloMATCH is structured into four tiers, each providing trial options at different stages of cancer treatment, from initial therapy to managing minimal residual disease.
• Researchers aim to enroll 5,000 or more patients, tracking their progress and biomarkers to evaluate clonal evolution and develop more effective therapies.
NIH Launches myeloMATCH Trial to Personalize Treatment for Myeloid Cancers
• The National Institutes of Health (NIH) has initiated the myeloMATCH clinical trial to evaluate precision medicine approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
• The trial will use rapid genetic testing to match patients with AML or MDS to targeted treatments based on the molecular characteristics of their tumors.
• myeloMATCH aims to enroll thousands of participants and will analyze blood and bone marrow samples to refine assays and understand treatment resistance mechanisms.
• This trial is part of the NCI's precision medicine initiatives, building on the NCI-MATCH trial to improve cancer treatment strategies.
NIH Launches myeloMATCH Precision Medicine Trial for Myeloid Cancers
• The NIH's myeloMATCH trial aims to match AML and MDS patients to targeted treatments based on their cancer's genetic profile, enhancing precision medicine.
• Newly diagnosed patients will undergo genetic testing to identify specific tumor characteristics, matching them to sub-studies or standard treatment based on findings.
• The trial will use increasingly sensitive tools to identify treatments for remaining cancer cells as the disease decreases, optimizing targeted drug combinations.
• As a successor to NCI-MATCH, myeloMATCH contributes to the Cancer Moonshot initiative, aiming to reduce cancer mortality and bring targeted treatments to patients.
myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS
• myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
• The program offers advanced biomarker testing to identify genomic and molecular features, matching patients with targeted treatments in a tiered approach across their treatment journey.
• Three treatment trials are now open, focusing on initial induction, residual disease, and consolidation therapy, with the goal of improving outcomes and developing new therapies for myeloid malignancies.
• The initiative aims to enroll 5,000 patients, tracking their progress and clonal evolution to refine treatments and address unmet needs in AML and MDS management.
© Copyright 2025. All Rights Reserved by MedPath